SCHEMBL9909766

SCHEMBL9909766

Cc1cnc2nccc(Oc3ccccc3)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.39
GCK P35557 4/20 0.39
CYP2D6 P10635 2/20 0.37
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 2/20 0.37
SLC6A3 Q01959 2/20 0.37
KCNH2 Q12809 1/20 0.37
PIK3C3 Q8NEB9 1/20 0.37
PTGS1 P23219 2/20 0.37
PTGS2 P35354 2/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
GRM5 P41594 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HTT P42858 2/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909767 0.88 ADORA1 (0.42) ADORA1GCKCYP2D6SLC6A2SLC6A4
SCHEMBL9909768 0.82 PLAU (0.39) KCNH2PIK3C3MEN1KMT2AL3MBTL1
SCHEMBL9909764 0.79 LTA4H (0.41) MEN1KMT2AL3MBTL1LMNAHTT
SCHEMBL9909769 0.73 PLAU (0.39) KCNH2MEN1KMT2AL3MBTL1LMNA
SCHEMBL7997563 0.68 PTGS1 (0.43) GCKPIK3C3PTGS1PTGS2LMNA
SCHEMBL10666290 0.67 PTGS1 (0.42) GCKPIK3C3PTGS1PTGS2KMT2A
SCHEMBL4989575 0.66 LTA4H (0.42) KMT2AHTTALDH1A1MAPT
SCHEMBL9909761 0.66 BRAF (0.52)
SCHEMBL9228553 0.65 MAPK8 (0.46) MEN1KMT2AL3MBTL1LMNASMN1; SMN2
SCHEMBL29733375 0.65 GCK (0.39) ADORA1GCKCYP2D6SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198279-B2 Pyrido[2,3-b]pyrazin-8-substituted compounds and their use INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2012-06-12 US disclosed
US-20100298320-A1 Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298320-A1 Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use BRAF, NRAS, RAF1 ADORA1 1320/4885GCK 1112/4885CYP2D6 1681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.